THRD stock icon

Third Harmonic Bio
THRD

$12.98
0.23%

Market Cap: 532M

 

About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Employees: 31

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

13% more funds holding

Funds holding: 63 [Q4 2023] → 71 (+8) [Q1 2024]

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0.93% less ownership

Funds ownership: 93.95% [Q4 2023] → 93.03% (-0.93%) [Q1 2024]

14% less capital invested

Capital invested by funds: $416M [Q4 2023] → $357M (-$58.5M) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$18
39%
upside
Avg. target
$21
58%
upside
High target
$23
77%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Stifel
Alex Thompson
77%upside
$23
Buy
Initiated
18 Jun 2024
Raymond James
Laura Prendergast
39%upside
$18
Outperform
Initiated
7 Jun 2024

Financial journalist opinion